|
1
|
Aquino SS, Gonçalves RP and Silva LB: The
pharmacotherapeutic follow-up of patients with chronic myeloid
leukemia (CML) on imatinib mesylate therapy. Rev Bras Hematol
Hemoter. 31:137–142. 2009. View Article : Google Scholar
|
|
2
|
Marzag H: Développement de nouvelles
réactions éco-compatibles: Application à la synthèse de molécules
bioactives. 2013.
|
|
3
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2014 update on diagnosis, monitoring, and
management. Am J Hematol. 89:547–556. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holyoake TL, Jiang X, Drummond MW, Eaves
AC and Eaves CJ: Elucidating critical mechanisms of deregulated
stem cell turnover in the chronic phase of chronic myeloid
leukemia. Leukemia. 16:549–558. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chu Y, Zhu H, Lv L, Zhou Y and Huo J:
MiRNAs in oesophageal squamous cancer. Neth J Med. 71:69–75.
2013.PubMed/NCBI
|
|
6
|
Mo MH, Chen L, Fu Y, Wang W and Fu SW:
Cell-free circulating miRNA biomarkers in cancer. J Cancer.
3:432–448. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arya D, Sachithanandan SP, Ross C,
Palakodeti D, Li S and Krishna S: MiRNA182 regulates percentage of
myeloid and erythroid cells in chronic myeloid leukemia. Cell Death
Dis. 8:e25472017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xishan Z, Ziying L, Jing D and Gang L:
MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL
oncogene in chronic myeloid leukemia. Sci Rep. 5:124602015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Song Y, Ma W, Zheng W and Yin H:
Decreased microRNA-30a levels are associated with enhanced ABL1 and
BCR-ABL1 expression in chronic myeloid leukemia. Leuk Res.
37:349–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu Y, Yang L, Zhao M, Zhu S, Kang R,
Vernon P, Tang D and Cao L: Targeting microRNA-30a-mediated
autophagy enhances imatinib activity against human chronic myeloid
leukemia cells. Leukemia. 26:1752–1760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Zhao L, Li N, Miao Y, Zhou H and Jia
L: miR-9 regulates the multidrug resistance of chronic myelogenous
leukemia by targeting ABCB1. Oncol Rep. 37:2193–2200. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Nohata N, Yamasaki T, Gotanda T,
Tachiwada T, et al: Novel oncogenic function of mesoderm
development candidate 1 and its regulation by MiR-574-3p in bladder
cancer cell lines. Int J Oncol. 40:951–959. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krishnan P, Ghosh S, Wang B, Li D,
Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O and
Damaraju S: Next generation sequencing profiling identifies
miR-574-3p and miR-660-5p as potential novel prognostic markers for
breast cancer. BMC Genomics. 16:7352015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ujihira T, Ikeda K, Suzuki T, Yamaga R,
Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, et
al: MicroRNA-574-3p, identified by microRNA library-based
functional screening, modulates tamoxifen response in breast
cancer. Sci Rep. 5:76412015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J,
Yang Q, Xu Y and Li F: Aberrant expression of microRNAs in gastric
cancer and biological significance of miR-574-3p. Int
Immunopharmacol. 13:468–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma L, Zhu Z, Jiang L, Sun X, Lu X, Zhou M,
Qian S and Jianyong L: Matrine suppresses cell growth of human
chronic myeloid leukemia cells via its inhibition of the
interleukin-6/Janus activated kinase/signal transducer and
activator of transcription 3 signaling cohort. Leuk Lymphoma.
56:2923–2930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu H, Liu X, Zhou J, Chen X and Zhao J:
miR-574-3p acts as a tumor promoter in osteosarcoma by targeting
SMAD4 signaling pathway. Oncol Lett. 12:5247–5253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okumura T, Kojima H, Miwa T, Sekine S,
Hashimoto I, Hojo S, Nagata T and Shimada Y: The expression of
microRNA 574-3p as a predictor of postoperative outcome in patients
with esophageal squamous cell carcinoma. World J Surg Oncol.
14:2282016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamasaki T, Kim EJ, Cerutti H and Ohama T:
Argonaute3 is a key player in miRNA-mediated target cleavage and
translational repression in Chlamydomonas. Plant J. 85:258–268.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong DS, Angelo LS and Kurzrock R:
Interleukin-6 and its receptor in cancer: Implications for
translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maeda K, Baba Y, Nagai Y, Miyazaki K,
Malykhin A, Nakamura K, Kincade PW, Sakaguchi N and Coggeshall KM:
IL-6 blocks a discrete early step in lymphopoiesis. Blood.
106:879–885. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reynaud D, Pietras E, Barry-Holson K, Mir
A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP and Passegué E:
IL-6 controls leukemic multipotent progenitor cell fate and
contributes to chronic myelogenous leukemia development. Cancer
Cell. 20:661–673. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ciarcia R, Vitiello MT, Galdiero M,
Pacilio C, Iovane V, d'Angelo D, Pagnini D, Caparrotti G, Conti D,
Tomei V, et al: Imatinib treatment inhibit IL-6, IL-8, NF-KB and
AP-1 production and modulate intracellular calcium in CML patients.
J Cell Physiol. 227:2798–2803. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar H, Tichkule S, Raj U, Gupta S,
Srivastava S and Varadwaj PK: Effect of STAT3 inhibitor in chronic
myeloid leukemia associated signaling pathway: A mathematical
modeling, simulation and systems biology study. 3 Biotech.
6:402016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baśkiewicz-Masiuk M and Machaliński B: The
role of the STAT5 proteins in the proliferation and apoptosis of
the CML and AML cells. Eur J Haematol. 72:420–429. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn
EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIA and
cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2
signaling in chronic myeloid leukemia K562 cells. Evid Based
Complement Alternat Med. 2013:8056392013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaymaz BT, Cetintaş VB, Aktan C and Kosova
B: MicroRNA-520a-5p displays a therapeutic effect upon chronic
myelogenous leukemia cells by targeting STAT3 and enhances the
anticarcinogenic role of capsaicin. Tumor Biol. 35:8733–8742. 2014.
View Article : Google Scholar
|
|
29
|
Selvi N, Kaymaz BT, Gündüz C, Aktan Ç,
Kiper HD, Şahin F, Cömert M, Selvi AF, Kosova B and Saydam G:
Bortezomib induces apoptosis by interacting with JAK/STAT pathway
in K562 leukemic cells. Tumor Biol. 35:7861–7870. 2014. View Article : Google Scholar
|
|
30
|
Cai H, Qin X and Yang C: Dehydrocostus
lactone suppresses proliferation of human chronic myeloid leukemia
cells through Bcr/Abl-JAK/STAT signaling pathways. J Cell Biochem.
118:3381–3390. 2017. View Article : Google Scholar : PubMed/NCBI
|
